FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for BRUKINSA (zanubrutinib) to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Graft-versus-host Disease
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)

Snippet

SUPPL AP for BRUKINSA (ZANUBRUTINIB)